Pernix Therapeutics Hldgs buy klostergang
Summary
This prediction ended on 07.12.15 with a price of €25.98. The price of Pernix Therapeutics Hldgs has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -14.29%. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Pernix Therapeutics Hldgs | - | - | - | - |
| iShares Core DAX® | 1.454% | 0.904% | 16.592% | 16.557% |
| iShares Nasdaq 100 | -0.913% | 3.463% | 36.062% | 50.205% |
| iShares Nikkei 225® | 2.355% | 3.830% | 14.881% | 10.110% |
| iShares S&P 500 | 0.283% | 2.639% | 29.599% | 44.509% |
Comments by klostergang for this prediction
In the thread Pernix Therapeutics Hldgs diskutieren
PTX is too cheap given its growth prospects and earnings trajectory!
Pernix Therapeutics (NASDAQ:PTX) is just one of a myriad small pharmaceuticals that have seen their stocks under pressure due to the fallout and collapse of Valeant Pharmaceuticals. After a big decline in its shares, the company reported blowout quarterly results this week.
At just $3.25 a share, the stock is too cheap given its growth prospects and earnings trajectory.
Earning Highlights: Pernix posted earnings of eight cents a share, seven cents a share above the consensus.Revenues climbed almost 55% year-over-year to just under $49 million for the quarter, just under $2 million above the consensus.Adjusted EBITDA increased to $8.7 million, compared to just under $7 million during the prior year period.
The company has three core products, Silenor, Treximit and Zohydro, that all have good growth prospects and decent patent expirations.